0.31
-4.59%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Actuate Therapeutics
From its filings with the US Securities and Exchange Commission
Actuate Therapeutics is based in Fort Worth, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ACTU. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $22.2m. At that date it held total assets of $14.0m and shareholders' equity of $7.9m.
500 patients with elraglusib as an IV injection (“Elraglusib Injection”) in Phase 1 and Phase 2 studies.
Part 3B study, is a randomized, controlled Phase 2 trial that enrolled 286 patients with no prior systemic treatment for metastatic disease.
Briggs J, Paluri R. Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review.
FOLFIRINOX and losartan in adults with untreated metastatic pancreatic adenocarcinoma. The IIT is being led by Colin Weekes, MD Ph.D.
NALIRIFOX was approved in February 2024 and may provide an alternative to FOLFIRINOX with a somewhat improved safety profile.
Therefore, we believe the ability to extend survival by even a few months would be considered meaningful in this patient population.
American Cancer Society, and neuroblastoma claims more lives of children under the age of 5 than any other cancer.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Aug 2024
- Employees
- 12
- Website
- actuatetherapeutics.com ↗
- Head office
- 1751 RIVER RUN, FORT WORTH, TX, 76107
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Aaron FletcherIndependent Chairman of the Board$124,306
- Mr. Daniel SchmittPresident, Chief Executive Officer, Director, since 2015$5.6m
- Mr. Paul LytleChief Financial Officer$1.9m
- Dr. Andrew MazarChief Operating Officer, since 2022$625,000
- Mr. Jason KeyesIndependent Director$222,061
- Ms. Amy RonnebergIndependent Director$213,112
- Dr. Roger SawhneyIndependent Director$213,112
- Mr. Todd ThomsonIndependent Director$111,242
- Dr. Daniel ZabrowskiIndependent Director$115,853
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Elraglusib Injection targets metastatic pancreatic ductal adenocarcinoma in clinical trials.
- The Phase I study evaluated the drug in 238 adult patients.
- GSK-3 inhibition mediates anti-tumor immunity and regulates immune checkpoints effectively.
Weaknesses
- The company employs only twelve staff members as of the listing.
- Actuate Therapeutics is a clinical stage firm without commercial products.
- High impact cancers like mPDAC remain difficult to treat currently.
Opportunities
- Elraglusib shows potential for treating neurodegenerative diseases beyond cancer indications.
- Small molecule design allows elraglusib to enter cancer cells efficiently.
- GSK-3b is a master regulator of signaling cascades in tumors.
Threats
- Competitors may develop superior therapies for metastatic pancreatic ductal adenocarcinoma.
- Phase I results might not confirm efficacy in larger trials.
- Regulatory hurdles could delay approval for the intravenous solution product.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.